Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug ...

Novavax said on Wednesday the U.S. Food and Drug Administration had asked the company to produce more data on its COVID-19 ...

Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

Novavax's vaccine has been available since 2022 in the U.S. after the FDA granted its emergency use. "We look forward to ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

Novavax has shared positive preliminary results from a real-world study of its JN.1-adapted COVID-19 vaccine. The SHIELD-Utah ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Brad Smith outlines the top stories on Wall Street as part of Yahoo Finance's Market Minute. Vertiv Holdings (VRT) stock is ...

Investing.com -- Novavax (NASDAQ: NVAX) shares surged 13% following the biotechnology company’s optimism about its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA).